Visit us at the annual ACR meeting!
The Scleroderma Clinical Trials Consortium (SCTC) represents the majority of researchers and clinicians in the world who have particular interest and expertise in the care of, and research in, scleroderma (systemic sclerosis). Each institution to which these researchers belong constitutes an individual member of the SCTC, but each researcher within that institution is also considered to be an important asset to the SCTC and is invited to attend the AGM and is, as well, on our mailing list and may participate in our working groups
As described in our mission statement, our goal is to advance knowledge about the treatment of scleroderma primarily by promoting efficient design, conduct, and reporting of results of clinical trials and observational studies. To this end we have created various working groups, all of which are listed on this website, that are studying various aspects of scleroderma. In general, they are concentrating on better ways to measure multiple aspects of the disease, which is essential for the conduct of good clinical trials and observational studies.
As we represent a large number of scleroderma researchers, we are also in a position to interface between those researchers and industry to help the latter in their design of clinical trials. We are also interested in helping industry develop efficient methods of trial recruitment.
The executive consists of a president, vice-president, secretary and treasurer. The executive meets along with past presidents and other interested parties once a month by teleconference. The AGM is held at the time of the ACR meeting.
Member Institutions have a dedicated clinic for the care of persons with scleroderma, or a large number of patients with scleroderma under the direct care of the Member. Member Institutions have participated in a previous clinical interventional trial of direct relevance to scleroderma and have published of at least one refereed manuscript describing clinical aspects of scleroderma within the previous five years. Provisional Members have participated in a previous clinical interventional trial for a non-scleroderma immunologic or rheumatologic disease, have support personnel experienced in clinical trials and “good clinical practices” and have demonstrated evidence of ability to recruit patients with scleroderma for clinical trials.
We are funded primarily from membership fees and donations from patient organizations and industry.
We are always happy to include more full or provisional members who wish to be a part of a global effort to find effective treatments of scleroderma.